Biomea Fusion, Inc. Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
Rhea-AI Summary
Biomea Fusion (Nasdaq: BMEA), a clinical-stage diabetes and obesity medicines company, has granted stock options to one new employee. The compensation committee approved non-qualified stock options to purchase 48,000 shares of common stock on September 24, 2025.
The stock options will vest quarterly over four years, with 1/16 of the shares vesting each quarter, contingent on continued employment. The grant was made under Biomea's 2023 Inducement Equity Plan, adopted on November 17, 2023, and complies with Nasdaq Listing Rule 5635(c)(4) as an employment inducement grant.
Positive
- None.
Negative
- None.
News Market Reaction – BMEA
In the Oct 1 session, BMEA gained 3.47%, reflecting a moderate positive market reaction. Argus tracked a peak move of +2.8% during that session. Our momentum scanner triggered 11 alerts that day, indicating notable trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SAN CARLOS, Calif., Oct. 01, 2025 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea” or the “Company”) (Nasdaq: BMEA), a clinical-stage diabetes and obesity medicines company, today announced that on September 24, 2025, the compensation committee of Biomea’s board of directors granted one new employee non-qualified stock options to purchase 48,000 shares of the Company’s common stock. The shares underlying each employee’s stock options will vest 1/16 on a quarterly basis over four years, subject to such employee’s continued employment with the Company on such vesting dates. The above-described award was made under Biomea’s 2023 Inducement Equity Plan (the “Plan”).
The above-described award was granted as an inducement material to the employee entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4) and was granted pursuant to the terms of the Plan. The Plan was adopted by Biomea’s board of directors on November 17, 2023.
About Biomea Fusion
Biomea Fusion is a clinical-stage diabetes and obesity medicines company focused on the development of its oral small molecules, icovamenib and BMF-650, both designed to significantly improve the lives of patients with diabetes, obesity, and metabolic diseases. We aim to cure.
Visit us at biomeafusion.com and follow us on LinkedIn, X and Facebook.
Contact:
Meichiel Jennifer Weiss
Sr. Director, Investor Relations and Corporate Development
IR@biomeafusion.com
